Advertisement
Canada markets closed
  • S&P/TSX

    22,059.03
    -184.99 (-0.83%)
     
  • S&P 500

    5,567.19
    +30.17 (+0.54%)
     
  • DOW

    39,375.87
    +67.87 (+0.17%)
     
  • CAD/USD

    0.7332
    -0.0015 (-0.20%)
     
  • CRUDE OIL

    83.44
    -0.44 (-0.52%)
     
  • Bitcoin CAD

    78,023.30
    -993.39 (-1.26%)
     
  • CMC Crypto 200

    1,183.86
    -24.84 (-2.05%)
     
  • GOLD FUTURES

    2,399.80
    +30.40 (+1.28%)
     
  • RUSSELL 2000

    2,026.73
    -9.90 (-0.49%)
     
  • 10-Yr Bond

    4.2720
    -0.0830 (-1.91%)
     
  • NASDAQ

    18,352.76
    +164.46 (+0.90%)
     
  • VOLATILITY

    12.48
    +0.22 (+1.79%)
     
  • FTSE

    8,203.93
    -37.33 (-0.45%)
     
  • NIKKEI 225

    40,912.37
    -1.28 (-0.00%)
     
  • CAD/EUR

    0.6762
    -0.0030 (-0.44%)
     

Medical Data Firm Tempus AI Raises $410.7 Million in IPO

(Bloomberg) -- Tempus AI Inc., a technology platform company using artificial intelligence to process medical data, priced its initial public offering at the top of a marketed range to raise $410.7 million.

Most Read from Bloomberg

Joining a rush of companies going public while touting their AI credentials, Tempus sold 11.1 million shares for $37 each after offering them for $35 to $37, according to a statement Thursday confirming an earlier report by Bloomberg News.

ADVERTISEMENT

At the IPO price, the company has a market value of $6.1 billion based on the outstanding shares listed in its filings with the US Securities and Exchange Commission.

Chicago-based Tempus AI, founded in 2015, describes its business as creating “intelligent diagnostics” for precision medicine.

The company’s platform connects laboratory results to a patient’s own clinical data, and has been used by more than 7,000 physicians across hundreds of provider networks, according to its filings. It has a team of about 2,300 employees, with about 250 of them holding medical degrees or doctorates.

Tempus AI had a net loss of $214 million on revenue of $532 million in 2023, compared with a net loss of $290 million on revenue of $321 million a year earlier, according to the filing.

The company’s largest investors include Eric Lefkofsky, the founder and chief executive officer, as well as a firm controlled by Kimberly Keywell and entities affiliated with Baillie Gifford & Co. The company has a dual-class share structure that will give Lefkofsky 65% of the shareholder voting power after the IPO.

The offering is being led by Morgan Stanley, JPMorgan Chase & Co. and Allen & Co. The company’s shares are expected to begin trading Friday on the Nasdaq Global Select Market under the symbol TEM.

(Updates with statement in second paragraph.)

Most Read from Bloomberg Businessweek

©2024 Bloomberg L.P.